Ratings by Guggenheim (Etzer Darout)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/18/2025 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 9/2/2025 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 4/15/2025 | Verve Therapeutics | VERV | Maintain | Buy (N/A) |
|
Details | ||
| 4/4/2025 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2023 | Onconova Therapeutics | ONTX | Maintain | Buy (N/A) |
|
Details | ||
| 11/1/2022 | Inventiva SA | IVA | Maintain | Buy (N/A) |
|
Details | ||
| 3/21/2022 | Verve Therapeutics | VERV | Maintain | Buy (N/A) |
|
Details | ||
| 9/13/2021 | Mirum Pharamceuticals | MIRM | Maintain | Buy (N/A) |
|
Details | ||
| 7/12/2021 | Verve Therapeutics | VERV | New Coverage | Buy (N/A) |
46.00 (11.13) |
-75.8% | Details | |
| 5/18/2021 | Vascular Biogenics Ltd | VBLT | New Coverage | Buy (N/A) |
2.02 (0.16) |
-92.08% | Details | |
| 5/18/2021 | Onconova Therapeutics | ONTX | New Coverage | Buy (N/A) |
0.62 (1.00) |
61.29% | Details | |
| 3/8/2021 | Soleno Therapeutics Inc. | SLNO | Maintain | Buy (N/A) |
|
Details | ||
| 10/30/2020 | DiaMedica Therapeutics Inc. | DMAC | New Coverage | Buy (N/A) |
4.13 (6.28) |
52.06% | Details | |
| 9/22/2020 | CytomX Therapeutics | CTMX | Downgrade | Neutral (Buy) |
6.94 (3.15) |
-54.61% | Details | |
| 9/22/2020 | Eidos Therapeutics | EIDX | Downgrade | Neutral (Buy) |
47.60 (122.21) |
156.74% | Details | |
| 8/4/2020 | Inventiva SA | IVA | New Coverage | Buy (N/A) |
10.24 (3.71) |
-63.77% | Details | |
| 6/1/2020 | MacroGenics | MGNX | Upgrade | Buy (Neutral) |
19.24 (4.69) |
-75.62% | Details | |
| 3/31/2020 | MyoKardia | MYOK | Maintain | Buy (N/A) |
|
Details | ||
| 3/31/2020 | CytomX Therapeutics | CTMX | Maintain | Buy (N/A) |
|
Details | ||
| 3/3/2020 | Forty Seven Inc. | FTSV | Downgrade | Neutral (Buy) |
93.91 (95.51) |
1.7% | Details | |
| 2/20/2020 | Eidos Therapeutics | EIDX | New Coverage | Buy (N/A) |
51.00 (122.21) |
139.63% | Details | |
| 2/4/2020 | Forty Seven Inc. | FTSV | Maintain | Buy (N/A) |
|
Details | ||
| 1/27/2020 | MyoKardia | MYOK | Maintain | Buy (N/A) |
|
Details | ||
| 1/6/2020 | CytomX Therapeutics | CTMX | Maintain | Buy (N/A) |
|
Details | ||
| 11/20/2019 | MacroGenics | MGNX | New Coverage | Neutral (N/A) |
8.67 (4.69) |
-45.91% | Details | |
| 11/20/2019 | CytomX Therapeutics | CTMX | New Coverage | Buy (N/A) |
5.17 (3.15) |
-39.07% | Details | |
| 9/20/2019 | Zealand Pharma A/S | ZEAL | New Coverage | Buy (N/A) |
24.88 (17.59) |
-29.3% | Details | |
| 9/20/2019 | MyoKardia | MYOK | New Coverage | Buy (N/A) |
55.63 (224.91) |
304.3% | Details |
